Canada is an attractive market for pharmaceutical manufacturers. While universal healthcare does not currently extend to drugs in an outpatient setting, most Canadian consumers have some form of drug coverage through...more
The Patented Medicine Prices Review Board (PMPRB) regulates the price of patented medicines in Canada by determining whether a price is excessive. The Board is revisiting its approach to pricing, and has now released a...more
The following are highlights of developments in Canadian life sciences intellectual property and regulatory law in 2016, updating our 2016 mid-year highlights.
1. Substantive patent law developments -
Utility and...more
1/11/2017
/ Administrative Proceedings ,
Anti-Competitive ,
Apotex ,
Arbitration ,
AstraZeneca ,
Bayer ,
Biologics ,
Biosimilars ,
CADTH ,
Calculation of Damages ,
CETA ,
Competition Authorities ,
Constitutional Challenges ,
Data Protection ,
Double Patent ,
Eli Lilly ,
Generic Drugs ,
Health Canada ,
Leave to Appeal ,
Life Sciences ,
NAFTA ,
New Guidance ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patent Terms ,
Patented Medicine Prices Review Board (PMPRB) ,
Patents ,
Pfizer ,
Pharmaceutical Patents ,
PMNOC Regulations ,
Supreme Court of Canada ,
Teva Pharmaceuticals ,
Trans-Pacific Partnership ,
Unjust Enrichment ,
Utility Patents